Olema Pharmaceuticals (OLMA) News Today

Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) shares were modestly higher as investors weighed fresh analyst support and a new finance executive against weaker earnings expectations and the company’s recent quarterly loss.

• Positive Sentiment: Olema appointed Jason O’Byrne as chief financial officer. The leadership addition could support financial planning, capital management and the company’s continued development efforts. Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer
• Positive Sentiment: Piper Sandler reaffirmed its Buy rating, while Goldman Sachs also initiated or reiterated a Buy view on OLMA. Continued bullish coverage may provide support for the stock and signals that analysts see substantial long-term value in Olema’s pipeline. Piper Sandler Reaffirms Their Buy Rating on Olema Pharmaceuticals Olema Pharmaceuticals Receives a Buy from Goldman Sachs
• Neutral Sentiment: JPMorgan lowered its price target to $46 from $52 but retained an Overweight rating. The target reduction is a negative revision, although it still implies considerable upside from recent trading levels. JPMorgan Revises Olema Pharmaceuticals Price Target
• Negative Sentiment: HC Wainwright reduced its EPS forecasts across 2026–2030, including estimates of losses of $2.44 per share in fiscal 2026 and $2.78 in 2027. The revisions point to expectations for larger or more persistent losses, despite the firm maintaining a Buy rating and $36 price target.
• Negative Sentiment: Olema’s latest quarterly results missed expectations, with a loss of $0.61 per share versus the consensus loss estimate of $0.55. Reports characterized the shares as gapping lower following the weak earnings, adding pressure to a stock already trading well below its 52-week high. Olema Pharmaceuticals Shares Gap Down Following Weak Earnings